Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408028 | 0.89 | GRIN1 (0.56) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19688701 | 0.88 | GRIN1 (0.67) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL29209237 | 0.88 | GRIN1 (0.67) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3990887 | 0.86 | GRIN1 (0.55) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3994021 | 0.84 | GRIN1 (0.58) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19386242 | 0.83 | GRIN1 (0.68) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL21220099 | 0.83 | GRIN1 (0.50) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL21231890 | 0.83 | GRIN1 (0.50) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19688879 | 0.83 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL4407465 | 0.83 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027854-A1 | Analgesic uses of norketamine and ketamine/norketamine prodrugs | Yaupon Therapeutics, Inc. (US) | 2009-02-25 | — | — | EP | claimed |
| JP-2006510618-A | — | — | 2006-03-30 | — | — | JP | claimed |
| EP-1567145-A1 | ANALGESIC USES OF NORKETAMINE AND KETAMINE/NORKETAMINE PRODRUGS | Yaupon Therapeutics, Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040248964-A1 | Analgesic uses of norketamine and ketamine/norketamine prodrugs | YAUPON THERAPEUTICS, INC. | 2004-12-09 | — | — | US | claimed |
| WO-2004045601-A1 | ANALGESIC USES OF NORKETAMINE AND KETAMINE/NORKETAMINE PRODRUGS | YAUPON THERAPEUTICS, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1567145-B1 | ANALGESIC USES OF (S)-NORKETAMINE | YAUPON THERAPEUTICS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2027854-A1 | Analgesic uses of norketamine and ketamine/norketamine prodrugs | Yaupon Therapeutics, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1567145-A1 | ANALGESIC USES OF NORKETAMINE AND KETAMINE/NORKETAMINE PRODRUGS | Yaupon Therapeutics, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040248964-A1 | Analgesic uses of norketamine and ketamine/norketamine prodrugs | YAUPON THERAPEUTICS, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004045601-A1 | ANALGESIC USES OF NORKETAMINE AND KETAMINE/NORKETAMINE PRODRUGS | YAUPON THERAPEUTICS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248964-A1 | Analgesic uses of norketamine and ketamine/norketamine prodrugs | OPRK1, OPRM1, OPRL1 | GRIN1 296/4885GRIN2A 105/4885SLC6A4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.